Low SOX2 expression marks a distinct subset of adenoid cystic carcinoma of the head and neck and is associated with an advanced tumor stage

• Verfasst von: Thierauf, Julia [VerfasserIn]
• Verfasst von: Affolter, Annette [VerfasserIn]
• Verfasst von: Laureano, Natalia K. [VerfasserIn]
• Verfasst von: Plinkert, Peter K. [VerfasserIn]
• Verfasst von: Heß, Jochen [VerfasserIn]
• Titel: Low SOX2 expression marks a distinct subset of adenoid cystic carcinoma of the head and neck and is associated with an advanced tumor stage
• Verf.angabe: Julia Thierauf, Stephanie E. Weissinger, Johannes A. Veit, Annette Affolter, Natalia K. Laureano, Dirk Beutner, Gregor Heiduschka, Lorenz Kadletz, Moritz Meyer, Alexander Quaas, Peter Plinkert, Thomas K. Hoffmann, Jochen Hess
• E-Jahr: 2018
• Jahr: March 29, 2018
• Umfang: 11 S.
• Fussnoten: Gesehen am 06.08.2019
• Titel Quelle: Enthalten in: PLOS ONE
• Ort Quelle: San Francisco, California, US : PLOS, 2006
• Jahr Quelle: 2018
• Band/Heft Quelle: 13 (2018,3) Artikel-Nummer e0194989, 13 Seiten
• ISSN Quelle: 1932-6203
• DOI: doi:10.1371/journal.pone.0194989
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Carcinogenesis
• Sach-SW: Carcinomas
• Sach-SW: Head and neck squamous cell carcinoma
• Sach-SW: Lung and intrathoracic tumors
• Sach-SW: Lymph nodes
• Sach-SW: Metastasis
• Sach-SW: Squamous cell lung carcinoma
• Sach-SW: Vimentin
• K10plus-PPN: 1670623440

Abstract

Introduction The transcription factor SOX2 has been identified as a lineage survival oncogene in squamous cell carcinoma and copy number gain is a common event in several human malignancies including head and neck cancer. However, the regulation and function of SOX2 during carcinogenesis as well as its prognostic value appears to be highly context dependent. As an example, high SOX2 expression in lung squamous cell carcinoma (SCC) is related to a favorable prognosis, while it is associated with poor outcome in lung adenocarcinoma. More recently, higher SOX2 levels and improved survival was also reported for head and neck SCC (HNSCC), and silencing of SOX2 expression in HNSCC cell lines revealed a mesenchymal-like phenotype with prominent vimentin expression. So far, SOX2 expression and its clinical relevance for other head and neck cancers, such as adenoid cystic carcinoma (HNACC) have not been sufficiently investigated. Material and methods SOX2, vimentin and E-cadherin expression was assessed by immunohistochemical staining on serial sections from formalin fixed and paraffin embedded tissue samples of a patient cohort (n = 45) with primary ACC and correlated with patient and tumor characteristics as well as survival. Results High SOX2 expression was found in 14 (31%) primary tumor specimens and was significantly correlated with a N0 lymph node status (p = 0.04), while low SOX2 expression was correlated with a solid growth pattern (p = 0.031). Of the 45 patients, 27 tumor samples resembled an EMT-like phenotype, as assessed by high vimentin and low E-cadherin levels. However, in HNACC SOX2 levels were neither correlated with vimentin nor with E-cadherin expression, further supporting a context dependent regulation and function of SOX2 in distinct tumor entities. Conclusion The absence of SOX2 was predominantly found in solid HNACC, which are characterized by a more aggressive phenotype in ACC. However, the underlying molecular mechanisms of SOX2 regulation and function in distinct HNACC subgroups remain to be fully elucidated.